Taiwan
- 18 years executive business management experiences in pharmaceutical & biotech industry - Leadership on marketing, sales, medical, and R&D, delivered high growth top line & bottom line - Taiwan and UK educated, with global business experience in US, China and APAC countries - Specialty: Oncology, Respiratory, Metabolic, Infectious Diseases, & Vaccine - Expertise: Drug commercialization, commercial innovation, businesses development, and cooperate management
- Full P&L responsibility on leading vaccine business with 10+ assets, across pediatric and adult vaccines, private and tender sectors. - Turnaround vaccine business to 70% growth in 12 months, triple the business 2021-2023 - Launch the top herpe zoster vaccine, meningitis vaccine, RSV vaccine in Taiwan - Spearhead the strategic re-launch of influenza vaccine, expanded coverage to over 2M people in 2025. - Leadership on over 100 people sales, marketing, and cross-functional team - Cooperate excellence and transformation management - Member of Taiwan LT Committee
- Direct commercial strategy of Lung Cancer - Chair cross-functional LC innovation board - Establish signed partnership with Siemens, GE and AI companies with digital solutions - Supervise central and regional business managers - Target therapy, immunotherapy
Drive launch readiness, business strategy, PAP/PSP, cooperate development of company pipelines
- Direct global business strategy for biologic brands; shape portfolio strategy of the novel pipeline - Lead business in US and commercial alliance with Abbvie for Ex-US market of anti-RSV mAb, $1 billion revenue in 2016 - Drive the development of nirsevimab/MEDI8897, novel mAb pipeline for RSV - HQ BD assessment